Registro de Financiación

English

 

COMO INVESTIGADORES PRINCIPALES

– “Personalización de los tratamientos antihipertensivos y analgésicos mediante un nuevo sistema computarizado basado en el modelado matemático de la red de regulación hemodinámica”. Instituto de Salud Carlos III, expediente PI18/00996. 2019 – 2021.

Detalles del proyecto

– “Desarrollo de un nuevo método diagnóstico para la monitorización de las secuelas subclínicas del daño renal agudo y de su progresión a la enfermedad renal crónica”. Junta de Castilla y León (Consejería de Educación), ref SA083G18. 2018-2020.

– “New diagnostic system for early detection of chronic kidney damage associated with tobacco use: preventive and personalized application”. Instituto de Salud Carlos III, ref PI17/01979. 2018-2020.

Detalles del proyecto

– “Identification of biomarkers of early kidney injury associated with tobacco use”. Fundación Memoria de D. Samuel Solórzano Barriuso. 2018.

– “Biomarkers of early diagnosis of contrast nephropathy in vascular percutaneous procedures”. Fundación Memoria de D. Samuel Solórzano Barriuso. 2018.

– “Innovative clinical decision support system to stratify patients and customize pharmacological antihypertensive and analgesic treatments”. Ministerio de Economía, Industria y Competitividad (MINECO). Ref.: EUIN2017-87355. 2018-2019.

– “New predictive diagnostic system of renal disease based on multiparametric integrative technology”. Instituto de investigación biomédica de Salamanca (IBSAL). Consejería de Sanidad, ref. BIO16/00001.

– “Development and validation of new soluble formulations of quercetin to enhance their therapeutic effect in the prevention of acute renal failure”. Lanzadera TC. Concurso desafío Universidad-Empresa. Plan TCUE, ref. Ed. 2015 Lanzadera TC. 2015.

– “Early diagnosis as strategy in reducing the incidence of acute renal failure and mortality associated to transcatheter aortic valve implantation”. Junta de Castilla y León. Consejería de Sanidad, ref. BIO/SA66/15. 2015.

– “Improved renal transplant outcome by identifying biomarkers of risk in the donor”. Fundación Memoria de D. Samuel Solórzano Barruso, ref. FS/17-2015. 2015-2016.

– “Development of a new diagnostic method for monitoring subclinical sequelae of acute kidney injuryand its progression to chronic kidney disease”. Instituto de Salud Carlos III, ref. PI15/01055. 2016-2018.

Detalles del Proyecto

– “Development of a prototype multiplex system by flow cytometry for a novel multiparametric etiopathogenic diagnosis of acute kidney injury”. Instituto de Salud Carlos III, ref. DTS15/00166. 2016-2017.

– “Learning Toxicology through Open Educational Resources”. Erasmus + Strategic Partnership Key action 2, ref. 2015‐1‐ES01‐KA203‐015957. 2015-2017.

– “Development of a new theranostic tool for custom application of cancer treatments”. Instituto de Salud Carlos III, ref. PI14/01776. 2015-2017.

– “Involvement of several angiogenic factors in the development of Paget’s disease of bone and its modulating role in the evolution of the disease”.  Junta de Castilla y León, Consejería de Educación, ref. IES095U14. 2015-2016.

– “Development and validation of new soluble formulations of quercetin to enhance their therapeutic effect in the prevention of acute renal failure”. Fundación FUESCYL – Banco de Santander. Desafío UNIV-EMP.  2014-2015.

– “Development of a new theranostic tool for custom application of cancer treatments”. Junta de Castilla y León. Consejería de Educación, ref. SA359U14. 2015-2016.

– “New preventive and personalized diagnostic system of acute kidney injury risk”. MINECO, ref. IPT-2012-0779-010000. 2012-2014.

– “Identification of new markers with diagnostic and prognostic ability in the evolution of renal transplant”. Junta de Castilla y León. Consejería de Sanidad, ref. BIO/SA69/14. 2013-2014.

– “Development of a new theranostic tool for custom application of cancer treatments”. Junta de Castilla y León. Consejería de Sanidad, ref BIO/SA20/14. 2013-2014.

– “Implication of several angiogenic factors in the development of Paget bone disease, and their modulatory role during renal disease progression”. Junta de Castilla y León, Consejería de Educación, ref. IES095U14. 2014-2015.

– “Identification of biomarkers for monitoring nephrotoxicity of new anti-cancer drug combinations”. Junta de Castilla y León, ref. BIO/SA54/14. 2014.

– “Identification of urinary markers of risk of acute nephropathy in patients subject to surgical and diagnostic procedures involving iodinated contrast media: application for preventive and personalized medicine”. Instituto de Salud Carlos III, ref. PI11/02278. 2012-2014.

– “Role and diagnostic utility of cardiotrophin-1 in renal hypertrophy and hypertensive and diabetic target organ damage”. Instituto de Salud Carlos III, ref. PI12/00959. 2012-2015.

– “Mejora del pronóstico en pacientes sometidos a reemplazo valvular aórtico percutáneo mediante la prevención de la nefrotoxicidad de los medios de contraste. Mutua Madrileña Automovilista. n/r. 2012-2014.

– Análisis del papel de la cardiotrofina 1 en el trasplante renal y en el daño en órgano diana originado en hipertensión y diabetes. Mutua Madrileña Automovilista. n/r. 2012-2013.

– “Identification of urinary biomarkers of predisposition to acute kidney injury induced by sobtoxic doses of aminoglycoside antibiotics”. Instituto de Salud Carlos III, ref. PI081900. 2009-2012.

– “Role of osteoprotegerin and endoglin in endotelial dysfunction in diabetic patients and in an in vivo experimental model of diabetes”. Instituto de Salud Carlos III, ref. PS09/01067. 2009-2011.

COMO SOCIOS

  • Urinary biomarkers in acquired scar nephropathy. Junta de Castilla y León. Consejería de Sanidad. Gerencia Regional de Salud. GRS 1601/A/17. 2018.
  • New tools for the monitoring of response to treatment with tolvaptan in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease with rapidly progressing risk factors. Junta de Castilla y León. Consejería de Sanidad. Gerencia Regional de Salud. GRS 1595/A/17. 2018.
  • Evaluation of the impact on renal function in the frail elderly due to recurrent urinary tract infections. Junta de Castilla y León. Consejería de Sanidad. Gerencia Regional de Salud. GRS 1598/A/17. 2018
  • Involvement of several angiogenic factors in the presence and evolution of Paget’s disease of bone”.  Junta de Castilla y León, Gerencia Regional de Salud, ref. GRS 969/A/14. 2014-2015.
  • Renal function and inflammatory markers in relation to cardiovascular morbidity and impaired renal function. Cohort study in general adult population: EPIRCE II Castilla y Leon”. Junta de Castilla y León, Gerencia Regional de Salud, ref. GRS 908/B/14. 2014-2015.
  • “HIV-Nephromics. New markers of nephrotoxicity induced by antiretrovirals in HIV+ patients”. Sociedade Portuguesa de Nefrologia. n/r. 2013-2014.
  • “Progression markers of chronic nephropathy in patients with hypertension and nephroangiosclerosis”. Instituto de Salud Carlos III, Instituto Carlos III, ref. PI10/01971. 2011-2013.
  • “Factors involved in accelerated vascular aging . EVA study Salamanca”. Regional Health Management, Ministry of Health, Castilla y Leon, GRS 1193/B/15. 2015-2016.